Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

OKYO Pharma Limited - Ordinary Shares (NQ: OKYO )

1.020 -0.030 (-2.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,914
Open 1.060
Bid (Size) 1.010 (10)
Ask (Size) 1.050 (10)
Prev. Close 1.050
Today's Range 1.000 - 1.060
52wk Range 0.8075 - 2.950
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
OKYO Pharma Announces Chairman Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire

Performance

YTD
-47.42%
-47.42%
1 Month
+2.00%
+2.00%
3 Month
-19.69%
-19.69%
6 Month
-29.17%
-29.17%
1 Year
-47.42%
-47.42%

More News

Read More
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Via Benzinga
OKYO Pharma CEO Interview to Air on Bloomberg TV
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Chairman Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
OKYO Pharma Announces Chairman Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
From OKYO Pharma LTD
Via GlobeNewswire
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Participation in May 2024 Investor Conferences
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
From OKYO Pharma LTD
Via GlobeNewswire
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Relief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage Study
Via Benzinga
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
From OKYO Pharma LTD
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.